Juno Therapeutics, Inc. (JUNO) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a sell rating to a hold rating in a research report sent to investors on Tuesday, August 29th.

Several other equities research analysts have also commented on JUNO. Zacks Investment Research lowered Juno Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 2nd. FBR & Co cut their price target on Juno Therapeutics from $30.00 to $29.00 and set a mkt perform rating for the company in a research note on Friday, May 5th. Wedbush reiterated a neutral rating and issued a $24.00 price target on shares of Juno Therapeutics in a research note on Friday, May 5th. Morgan Stanley cut their price target on Juno Therapeutics from $27.00 to $26.00 and set an equal weight rating for the company in a research note on Monday, May 8th. Finally, Vetr raised shares of Juno Therapeutics to a buy rating in a report on Tuesday, May 23rd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $34.88.

Juno Therapeutics (NASDAQ JUNO) traded up 7.54% during trading on Tuesday, hitting $45.33. The stock had a trading volume of 4,269,525 shares. The stock has a 50 day moving average of $32.75 and a 200 day moving average of $26.72. The firm’s market capitalization is $4.75 billion. Juno Therapeutics has a one year low of $17.52 and a one year high of $45.75.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). The company had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.64) earnings per share. Equities research analysts expect that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/09/13/juno-therapeutics-inc-juno-upgraded-to-hold-at-valuengine.html.

In other Juno Therapeutics news, Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average cost of $24.40 per share, with a total value of $219,600.00. Following the completion of the acquisition, the director now directly owns 66,301 shares in the company, valued at approximately $1,617,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the transaction, the director now directly owns 783,536 shares in the company, valued at $33,425,645.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,078,369 shares of company stock worth $218,620,477. Corporate insiders own 15.26% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its holdings in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth $105,000. QS Investors LLC acquired a new stake in shares of Juno Therapeutics during the second quarter worth $135,000. Great West Life Assurance Co. Can lifted its stake in shares of Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the period. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of Juno Therapeutics during the first quarter worth $200,000. 70.76% of the stock is currently owned by institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply